Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
117.9 USD | +0.51% | -6.67% | +22.25% |
Financials (USD)
Sales 2024 * | 1.81B | Sales 2025 * | 2.91B | Capitalization | 11.06B |
---|---|---|---|---|---|
Net income 2024 * | 205M | Net income 2025 * | 1.05B | EV / Sales 2024 * | 5.42 x |
Net cash position 2024 * | 1.27B | Net cash position 2025 * | 2.39B | EV / Sales 2025 * | 2.98 x |
P/E ratio 2024 * |
51.9
x | P/E ratio 2025 * |
10.8
x | Employees | 1,314 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 95.22% |
Latest transcript on Sarepta Therapeutics, Inc.
1 day | +0.51% | ||
1 week | -5.27% | ||
Current month | -8.94% | ||
1 month | -4.90% | ||
3 months | +0.93% | ||
6 months | +3.58% | ||
Current year | +22.25% |
Managers | Title | Age | Since |
---|---|---|---|
Douglas Ingram
CEO | Chief Executive Officer | 61 | 17-06-25 |
Ian Estepan
DFI | Director of Finance/CFO | 48 | 14-12-31 |
Bilal Arif
CTO | Chief Tech/Sci/R&D Officer | - | - |
Members of the board | Title | Age | Since |
---|---|---|---|
Douglas Ingram
CEO | Chief Executive Officer | 61 | 17-06-25 |
M. Wilsey
CHM | Chairman | 71 | 09-03-30 |
Richard Barry
BRD | Director/Board Member | 65 | 15-06-01 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
4.63% | 1 M€ | -1.52% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-04-17 | 117.9 | +0.51% | 546,083 |
24-04-16 | 117.3 | -0.86% | 592,917 |
24-04-15 | 118.3 | -3.71% | 860,486 |
24-04-12 | 122.9 | -1.27% | 656,117 |
24-04-11 | 124.4 | -1.47% | 618,223 |
Delayed Quote Nasdaq, April 17, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+22.25% | 11.01B | |
-3.39% | 102B | |
+2.61% | 96.09B | |
-1.02% | 22.05B | |
-18.14% | 20.81B | |
-6.87% | 19.06B | |
-40.70% | 16.05B | |
-26.89% | 14.01B | |
+1.12% | 13.38B | |
-18.85% | 9.12B |
- Stock Market
- Equities
- SRPT Stock